Translational Hepatology From Bedside to Global Policy: How Robust Clinical and Translational Research Reshapes Global Practice Guidelines and Patient Outcomes
Journal of Gastroenterology and Hepatology · 2026-11 · 41 (11) · 3356-3366
DOI: 10.1111/jgh.70742 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Journal of Gastroenterology and Hepatology, online erschienen am 21.09.2026. Verfasst von George Lau. Beteiligte Einrichtung: Humanity and Health Clinical Trial Center, Humanity and Health Medical Group, Hong Kong SAR, China. Hauptthemen laut MEDLINE: Translational Research, Biomedical, Practice Guidelines as Topic, Gastroenterology. Die Arbeit nennt 38 Literaturangaben. Gefördert von: Humanity and Health Clinical Trial Center, Hong Kong SAR, China.
Abstract (Originalsprache)
Over four decades, translational hepatology has evolved from empirical observations into an evidence‐driven discipline. This review synthesizes key bedside discoveries, mechanistic studies, prospective cohorts, cross‐regional health‐economic evaluations, and landmark randomized controlled trials (RCTs) by our team that have helped to reshape regulatory drug approvals, Boxed Warnings, and international practice guidelines across APASL, AASLD, and EASL. First, clinical trials established the biphasic model and risk predictors of immunosuppression‐induced hepatitis B virus (HBV) reactivation, proving that pre‐emptive nucleos(t)ide analogue (NUC) prophylaxis prevents liver failure and antineoplastic disruptions. Second, multinational Phase III registration trials of finite 48‐week pegylated interferon alfa‐2a (Peg‐IFN α‐2a) in chronic hepatitis B (CHB)—combined with intrahepatic cccDNA kinetics, adoptive immunity transfer, and 30‐year Asia‐Pacific Markov health‐economic modeling—established response‐guided rules and validated finite Peg‐IFN switch/add‐on strategies as clinically dominant and cost‐effective. Third, prospective cohorts uncovered direct‐acting antiviral (DAA)–induced HBV reactivation during HCV clearance, establishing mandatory regulatory Boxed Warnings and pre‐DAA screening. Fourth, the Phase III HIMALAYA study and pooled Greater China (Mainland China, Hong Kong, Taiwan) cohorts validated the STRIDE regimen (single‐dose tremelimumab plus regular durvalumab) as frontline dual immunotherapy for unresectable hepatocellular carcinoma (uHCC), establishing marked survival benefit in HBV‐predominant populations (median OS 25.26 vs. 14.09 months) alongside a vascular endothelial growth factor (VEGF)–free standard for cirrhotic portal hypertension within APASL guidelines. Finally, translational insights across metabolic dysfunction, COVID‐19, ACLF, artificial intelligence (AI), and functional cure frameworks inform the APASL 2026 “treat‐all” CHB paradigm.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Humanity and Health Clinical Trial Center, Humanity and Health Medical Group, Hong Kong SAR, China.
- Zhongshan Hospital, Fudan University, Shanghai, China.
ORCID-Profile: George Lau
Förderung
- Humanity and Health Clinical Trial Center, Hong Kong SAR, China
Zitieren
APA
Lau, G. (2026). Translational Hepatology From Bedside to Global Policy: How Robust Clinical and Translational Research Reshapes Global Practice Guidelines and Patient Outcomes. Journal of Gastroenterology and Hepatology, 41(11), 3356-3366. https://doi.org/10.1111/jgh.70742
Vancouver
Lau G. Translational Hepatology From Bedside to Global Policy: How Robust Clinical and Translational Research Reshapes Global Practice Guidelines and Patient Outcomes. Journal of Gastroenterology and Hepatology. 2026;41(11):3356-3366. doi:10.1111/jgh.70742
BibTeX
@article{Lau2026,
author = {Lau, George},
title = {Translational Hepatology From Bedside to Global Policy: How Robust Clinical and Translational Research Reshapes Global Practice Guidelines and Patient Outcomes},
journal = {Journal of Gastroenterology and Hepatology},
year = {2026},
volume = {41},
number = {11},
pages = {3356--3366},
doi = {10.1111/jgh.70742}
}
EUVIMED